Label Update for Cabotegravir and Rilpivirine Long-Acting HIV Treatment
March 24th 2022With FDA Approval, the oral lead-in for the cabotegravir and rilpivirine long-acting HIV treatment (Cabenuva) is now optional. Clinical trial data showed similar safety and efficacy profiles for initiating the therapy with or without the oral lead-in.
“Ramp Up the Resources”: Increased Effort and Funding Needed to End HIV
March 23rd 2022Congress’s spending bill allocated drastically less funding for HIV testing, prevention, and treatment than previously promised. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, explains why it is so vital to continue the fight against HIV.
Type 2 Diabetes Diagnosis More Likely After COVID-19 Infection
March 21st 2022A matched cohort study found COVID-19 infection increased the risk of new type 2 diabetes diagnosis. Compared to patients with acute upper respiratory tract infections, COVID-19 patients were 28% more likely to develop diabetes.
Children’s Duration of COVID-19 Immunity from Natural Infection
March 19th 2022A Texas study found children and adolescents who previously contracted COVID-19 retained protective antibodies for 6 or more months after infection. However, natural infection plus vaccination remains the best defense against COVID-19.
“We Treat People With Dignity”: An Alternative Healthcare Clinic for People Who Use Drugs
March 18th 2022People who use drugs face obstacles, like homelessness and stigma, that hinder their access to healthcare. Dr. Brianna Norton opened the Montefiore-NYHRE Clinic, a first-of its kind academic medical center, to serve marginalized people holistically and respectfully.
No Increased Risk of Neurological Conditions After COVID-19 Vaccination
March 17th 2022A study of over 8 million participants found no correlation between COVID-19 vaccination and developing neurological conditions. However, a risk of some neurological conditions was increased after COVID-19 infection.